Major progress for a less common cancer

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 6-8

  Fleming, Gini F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GESTAGEN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; EDITORIAL; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; HUMAN; INCIDENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; UTERUS CANCER; ABDOMEN; ENDOMETRIUM TUMOR; FEMALE; MORTALITY; NOTE; RADIATION EXPOSURE;

ABDOMEN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING;

EID: 33644835823     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8836     Document Type: Editorial

References (11)

1. Jemal A, Murray T, Ward E, et al: Cancer Sstatistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Creasman WT, Odicino F, Maisonneuve P, et al: Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83:79-118, 2003 (suppl 1)
3. Macdonald RR, Thorogood J, Mason MK: A randomized trial of progestogen in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 95:166-174, 1988
4. Kauppila A: Progestin therapy of endometrial, breast and ovarian carcinoma: A review of clinical observations. Acta Obstet Gynecol Scand 63:441-450, 1984
5. De Palo G, Mangioni C, Periti P, et al: Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups: Long-term results of a randomized multicenter study. Eur J Cancer 29:1133-1140, 1993
6. Randall ME, Filiaci VL, Muss H, et al: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 24:36-44, 2006
7. Sagae S, Udagawa Y, Susumu N, et al: Randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma. J Clin Oncol 23:455, 2005 (suppl; abstr 5002)
8. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, et al: Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22:1234-1241, 2004
9. Creasman WT, Kohler MF, Odincion F, et al: Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium Gynecol Oncol 95:593-596, 2004
10. McMeekin DS, Filiaci VL, Thigpen T, et al: Importance of histology in advanced and recurrent endometrial cancer patients participating in 1st line chemotherapy trials: A Gynecologic Oncology Group (GOG) Trial. Gynecol Oncol 96:940, 2005 (abstr 69)
11. Muggia FM: Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Semin Oncol 31:17-24, 2004 (suppl 14)